Virus Yield Reduction Assay
Currently, various techniques are used to evaluate the antiviral activity of compounds against viruses. Some of the more commonly used procedures include plaque reduction, dye uptake, nucleic acid hybridization, and enzyme-linked immunosorbent assay. A less commonly used technique is the virus yield reduction assay. In this procedure, the virus-infected culture is incubated with antiviral compounds for a period of time to allow the virus to replicate, and then a separate monolayer culture is used to titrate the new progeny viruses. Although virus yield reduction assay can quantitatively measure the production of infectious virus particles in drug-treated cultures, the labor-intensive nature of this assay has so far prevented its widespread use as a conventional technique. To simplify this test, we modified it to use microtitration technology.
Some advantages of the yield reduction assay are: (A) The multiplicity of infection (MOI) of the virus is high enough to infect approximately 100% of the cells; (B) The effects of the decay of antiviral activity during the time the virus is replicating in the cells is minimal; and (C) by titrating progeny viruses in cell types that allow virus plaques, high accuracy can be obtained.
The virus yield reduction assay is mainly divided into three steps: infect the cells in the presence of different concentrations of the test substance; collect the cells or cell culture supernatants after the virus replication cycle; determine the virus titer by plaque analysis, TCID50 or quantitative real-time PCR.
Creative Diagnostics offers comprehensive services for virus yield reduction assay. We use microtitration technology to simplify the entire assay, greatly reducing the required operations.
Our Procedures
Our Features
- Using microtitration technology to save your time.
- Allowing a high throughput process.
- More reliable for evaluating the inhibitory effects on viral replication.
- Permitting the measurement of more profound drug effects by the use of a higher MOI and the quantitation of progeny virus, determining a much greater antiviral activity range (1-106 PFU/ml).
Our Capabilities
- Dengue virus (DENV)
- Herpes simplex virus (HSV)
- Human cytomegalovirus (HCMV)
- Human influenza A virus
- Sindbis virus (SINV)
(Other viruses or microorganisms may be available on request)
We combine infection and analytical expertise to provide our clients with the most powerful portfolio of antiviral and antimicrobial in vitro testing services. Facing an increasing demand for new antiviral and antimicrobial compounds for the treatment of infectious diseases, Creative Diagnostics can test these compounds in vitro to determine their potential efficacy in vivo models.
